See more : Uniinfo Telecom Services Limited (UNIINFO.NS) Income Statement Analysis – Financial Results
Complete financial analysis of GRI Bio, Inc. (GRI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of GRI Bio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- GGToor, Inc. (GTOR) Income Statement Analysis – Financial Results
- SHRADDHA PRIME PROJECTS LTD (SHRADDHA.BO) Income Statement Analysis – Financial Results
- KATITAS CO., Ltd. (8919.T) Income Statement Analysis – Financial Results
- E J Holdings Inc. (2153.T) Income Statement Analysis – Financial Results
- Sycamore Entertainment Group, Inc. (SEGI) Income Statement Analysis – Financial Results
GRI Bio, Inc. (GRI)
About GRI Bio, Inc.
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 21.77M | 0.00 | 0.00 | 100.00K | 0.00 | 0.00 |
| Cost of Revenue | 57.00K | 206.00K | 73.00K | 0.00 | 735.00 | 612.00 |
| Gross Profit | 21.71M | -206.00K | -73.00K | 100.00K | -735.00 | -612.00 |
| Gross Profit Ratio | 99.74% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 3.23M | 242.00K | 249.00K | 3.71M | 1.88M | 3.51M |
| General & Administrative | 1.49M | 2.00M | 813.00K | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 2.96M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 8.10M | 2.00M | 813.00K | 1.11M | 1.27M | 800.08K |
| Other Expenses | 102.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 11.33M | 2.24M | 1.06M | 4.81M | 3.15M | 4.31M |
| Cost & Expenses | 11.39M | 2.24M | 1.06M | 4.89M | 3.15M | 4.31M |
| Interest Income | 0.00 | 26.00K | 0.00 | 0.00 | 0.00 | 1.06K |
| Interest Expense | 2.08M | 653.00K | 547.00K | 34.00K | 197.03K | 0.00 |
| Depreciation & Amortization | 57.00K | 50.00K | 73.00K | 75.00K | 735.00 | 612.00 |
| EBITDA | -10.90M | -2.51M | -9.21M | -4.71M | -3.27M | -4.31M |
| EBITDA Ratio | -50.07% | 0.00% | 0.00% | -4,713.00% | 0.00% | 0.00% |
| Operating Income | -11.39M | -2.24M | -1.06M | -4.79M | -3.15M | -4.31M |
| Operating Income Ratio | -52.31% | 0.00% | 0.00% | -4,788.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.65M | -978.00K | -8.24M | -34.00K | -310.07K | 1.06K |
| Income Before Tax | -13.04M | -3.22M | -1.56M | -4.82M | -3.46M | -4.31M |
| Income Before Tax Ratio | -59.89% | 0.00% | 0.00% | -4,822.00% | 0.00% | 0.00% |
| Income Tax Expense | 2.77M | 325.00K | -50.00K | -131.30K | 5.00 | -2.00 |
| Net Income | -13.04M | -3.54M | -1.51M | -4.82M | -3.46M | -4.31M |
| Net Income Ratio | -59.89% | 0.00% | 0.00% | -4,822.00% | 0.00% | 0.00% |
| EPS | -28.25 | -8.43 | -4.65 | -14.87 | -10.68 | -1.73K |
| EPS Diluted | -28.25 | -8.43 | -4.65 | -14.87 | -10.68 | -1.73K |
| Weighted Avg Shares Out | 461.57K | 420.00K | 324.42K | 324.33K | 324.33K | 2.49K |
| Weighted Avg Shares Out (Dil) | 461.57K | 420.00K | 324.42K | 324.33K | 324.33K | 2.49K |
GRI Bio Announces Reverse Stock Split
GRI's common stock is expected to begin trading on a post-split adjusted basis on January 30, 2024 LA JOLLA, CA, Jan. 26, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing...
GRI Bio Commences Patient Enrollment in Phase 2a Biomarker Study Evaluating Lead Program GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)
Clinical development plan potentially leveraging 505(b)(2) regulatory pathway Currently available treatments for IPF are limited to only two approved drugs that come with significant side-effects, limited patient compliance and no impact on survival 1 LA JOLLA, CA, Dec. 05, 2023...
GRI Bio (NASDAQ: GRI) Announces FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant NKT (“iNKT”) Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)
Clinical development plan leveraging 505(b)(2) regulatory pathway Initiation of Phase 2a biomarker study on track to start before year end Currently available treatments for IPF are limited to only two approved drugs that come with significant side-effects, limited compliance and...
GRI Bio (NASDAQ: GRI) Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Phase 2a biomarker study of GRI-0621 for Idiopathic Pulmonary Fibrosis (“IPF”) on track to start before year end 2023; Interim data expected H1 2024
GRI Bio Presents Data Supporting Innovative Pipeline of NKT Cell Modulators for the Treatment of High-Value Inflammatory, Fibrotic and Autoimmune Diseases
Data presented at the 7 th Annual Antifibrotic Drug Development (AFDD) Summit Company's lead program, GRI-0621, has demonstrated ability to inhibit the activity of type I invariant NKT (iNKT) cells early in the inflammatory cascade to prevent cytokine release, cellular...
GRI Bio Presents Translational Data Demonstrating Connection Between NKT Cells and the Pathogenesis of Idiopathic Pulmonary Fibrosis (IPF) at the 2023 Pittsburgh-Ireland International Lung Conference
Findings demonstrate that the number of NKT cells positively correlates with the number of airway macrophages in IPF patients
GRI Bio Announces Partnership with the Respiratory Translational Research Collaboration to Advance Leading NKT Regulation Technology Targeting Earlier in the Inflammatory Cascade to Modulate Disease Progression
UK consortia brings together internationally recognized investigators in the UK's leading centers of excellence to carry out experimental and early phase research
GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Ask the CEO Conference
- Live moderated webcast with Marc Hertz, Chief Executive Officer of GRI Bio on Tuesday, October 24 th at 11:00 AM ET
GRI Bio Announces Publication of Comprehensive Invariant NKT (iNKT) Cell Review in Frontiers in Immunology Demonstrating a Key Role of Type 1 iNKT Cells in Modulating Various Fibrotic Conditions
In several murine models of chronic inflammation and fibrosis, as well as in humans, it has been shown that iNKT cells are selectively activated in the disease setting
September Is Pulmonary Fibrosis Awareness Month: Here's What One Company Is Doing To Develop A Treatment For This Deadly Disease
LA JOLLA, CA / ACCESSWIRE / September 29, 2023 / September is Pulmonary Fibrosis Awareness Month - a time dedicated to raising public consciousness and understanding about this devastating lung disease. Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive and...
Source: https://incomestatements.info
Category: Stock Reports